
Releases
Aardvark Therapeutics Faces Investor Lawsuit Over Drug Safety Disclosures
A 32 percent single-day stock plunge on May 15, 2026, has ignited a fresh legal challenge against Aardvark Therapeutics. The collapse followed an FDA decision to place a clinical hold on the company’s lead drug candidate, ARD-101, casting significant doubt on previous company assurances regarding the treatment's safety profile.


.png)











:max_bytes(150000):strip_icc()/how-to-clean-outside-dryer-vent-2145966-03-59e94e1b999542cb980e604a4135f3d3.jpg)








